The effect of exogenous glucose-dependent insulinotropic polypeptide in combination with glucagon-like peptide-1 on glycemia in the critically ill

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) have additive insulinotropic effects when coadministered in health. We aimed to determine whether GIP confers additional glucose lowering to that of GLP-1 in the critically ill. Twenty mechanically ventilated crit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes care 2013-10, Vol.36 (10), p.3333-3336
Hauptverfasser:	Lee, Michael Y, Fraser, Jonathan D, Chapman, Marianne J, Sundararajan, Krishnaswamy, Umapathysivam, Mahesh M, Summers, Matthew J, Zaknic, Antony V, Rayner, Christopher K, Meier, Juris J, Horowitz, Michael, Deane, Adam M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Blood Glucose - drug effects Critical Illness Cross-Over Studies Diabetes Double-Blind Method Female Gastric Inhibitory Polypeptide - administration & dosage Gastric Inhibitory Polypeptide - therapeutic use Glucagon-Like Peptide 1 - administration & dosage Glucagon-Like Peptide 1 - therapeutic use Glucose Humans Hyperglycemia Hyperglycemia - drug therapy Insulin Male Middle Aged Original Research Polypeptides Prospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!